Neuraly Reports the Completion of Patient Enrollment in P-II Study of NLY01 for the Treatment of Parkinson’s Disease
Shots:
- The company has completed the patient enrollment in the P-II study to evaluate the safety, tolerability & efficacy of NLY01 (2.5/5mg) vs PBO in 255 patients with PD across 60 clinical sites in the US & Canada for 36wks. The results are expected in H1’23
- NLY01 has shown the ability to inhibit neuroinflammation & prevent neuronal cell death, slow disease progression, improved motor, and cognitive functions & extended the lifespan in mice with PD, was well-tolerated
- In the P-I trial, NLY01 was found to be well-tolerated and provides near-continuous exposure to target therapeutic levels with qw dosing & demonstrated an impressive PH profile at a half-life of 12.5 days
Ref: Businesswire | Image: Neuraly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
